BridgeBio Pharma had its Relative Strength (RS) Rating upgraded from 79 to 89 Tuesday.
This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks matches up against the rest of the market.
Over 100 years of market history reveals that the best-performing stocks often have an 80 or better RS Rating in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
BridgeBio Pharma has risen more than 5% past a 30.51 entry in a first-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
The company showed 0% earnings growth in its most recent report. Revenue rose -33%. Keep an eye out for the company's next round of numbers on or around Feb. 20.
BridgeBio Pharma earns the No. 176 rank among its peers in the Medical-Biomed/Biotech industry group. Halozyme Therapeutics, Catalyst Pharmaceuticals and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
